Siamak Daneshmand, MD

BIOGRAPHY
Dr. Sia Daneshmand is currently Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California (USC) in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the AUA Guidelines panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of the SUO Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials and has led over a dozen clinical trials in bladder cancer and a pivotal investigator initiated mutli-institutional trial in testicular cancer (SEMS). He is current secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 13 consecutive years. He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored or co-authored over 400 peer-reviewed articles, reviews, and book chapters.

• Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. JAMA Netw Open. 2026 Jul 01; 9(7):e2623622.. View in PubMed
• Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer. Eur Urol. 2026 Jun 17.. View in PubMed
• How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e516212.. View in PubMed
• Active surveillance in low-grade NMIBC – results of an international two-round modified Delphi consensus. Nat Rev Urol. 2026 Apr 01.. View in PubMed
• Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model. Eur Urol Focus. 2026 Mar 20.. View in PubMed
• Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026 Jun; 89(6):500-511.. View in PubMed
• Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proc Natl Acad Sci U S A. 2026 Feb 24; 123(8):e2533449123.. View in PubMed
• Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. medRxiv. 2026 Jan 16.. View in PubMed
• Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series. Urol Oncol. 2026 Mar; 44(3):110984.. View in PubMed
• Safety of omitting pelvic imaging in patients with stage I germ cell tumor (GCT) on surveillance: A multi-institutional study. Urol Oncol. 2026 Mar; 44(3):110966.. View in PubMed
• Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients? Int J Urol. 2026 Jan; 33(1):e70330. Zahir M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, M . View in PubMed
• Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. J Clin Oncol. 2026 02; 44(4):274-285.. View in PubMed
• Impact of neighborhood deprivation on bladder cancer outcomes: A regional analysis. Bladder Cancer. 2025 Oct-Dec; 11(4):23523735251406621.. View in PubMed
• Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncol Pract. 2025 Nov 18.. View in PubMed
• Prevalence of Fertility Preservation Counseling and Sperm Cryopreservation Amongst Males With Testicular Cancer. Urology. 2026 Feb; 208:83-87.. View in PubMed
• Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. Eur Urol. 2026 Feb; 89(2):165-173.. View in PubMed
• Management of clinical stage T3/T4 bladder cancer: a review. World J Urol. 2025 Sep 29; 43(1):583.. View in PubMed
• End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2025 11 10; 43(32):3536-3544.. View in PubMed
• Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. J Clin Oncol. 2025 Oct 10; 43(29):3231.. View in PubMed
• Late relapse of testicular germ cell tumor: An individual patient data meta-analysis of disease characteristics, treatments, and oncological outcomes. Cent European J Urol. 2025; 78(3):289-304.. View in PubMed
• Outcomes of Reinduction With Nadofaragene Firadenovec. J Urol. 2025 Nov; 214(5):472-473.. View in PubMed
• TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. J Clin Oncol. 2025 11 20; 43(33):3578-3588.. View in PubMed
• Oncological outcomes of open versus minimally invasive nephroureterectomy for locally advanced upper tract urothelial carcinoma. World J Urol. 2025 Jul 23; 43(1):452.. View in PubMed
• Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder. Urologie. 2026 Feb; 65(2):162-170.. View in PubMed
• Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes. Eur Urol. 2025 Oct; 88(4):411-413.. View in PubMed
• Key Updates in Testicular Cancer: Optimizing Survivorship and Survival. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e472654.. View in PubMed
• Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026 Jan; 89(1):18-28.. View in PubMed
• Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. J Urol. 2025 09; 214(3):272-279.. View in PubMed
• Diagnostic efficacy of serum microRNAs in predicting pathology of retroperitoneal lymph node dissection in patients with testicular germ cell tumors: a systematic review and meta-analysis. World J Urol. 2025 Mar 27; 43(1):192.. View in PubMed
• The association between perioperative activity levels and discharge outcomes after radical cystectomy. Urol Oncol. 2025 08; 43(8):468.e1-468.e6.. View in PubMed
• Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. NPJ Digit Med. 2025 Mar 22; 8(1):174.. View in PubMed
• Bladder Preservation: An Overview of Novel Prospects and Limitations. Int J Urol. 2025 Jun; 32(6):756-757.. View in PubMed
• Identification of genes associated with testicular germ cell tumor susceptibility through a transcriptome-wide association study. Am J Hum Genet. 2025 03 06; 112(3):630-643.. View in PubMed
• Serum Tumor Markers for Muscle-Invasive Bladder Cancer in Clinical Practice: A Narrative Review. Cancers (Basel). 2025 Feb 21; 17(5).. View in PubMed
• Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy. Eur Urol Open Sci. 2025 Mar; 73:24-30.. View in PubMed
• Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Urol Oncol. 2025 05; 43(5):286-296.. View in PubMed
• Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2025 Apr; 135(4):621-628.. View in PubMed
• Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review. Eur Urol. 2025 Apr; 87(4):427-441.. View in PubMed
• Driver mutations associated with signatures of platinum sensitivity in germ cell tumors. NPJ Precis Oncol. 2024 Nov 02; 8(1):249.. View in PubMed
• A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. BJU Int. 2025 Apr; 135(4):648-656.. View in PubMed
• Reply by Authors. J Urol. 2025 Jan; 213(1):70.. View in PubMed
• Disparities in Testicular Cancer: A Review of the Literature. Cancers (Basel). 2024 Oct 10; 16(20).. View in PubMed
• Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.. View in PubMed
• Residual cancer at radical cystectomy with or without neoadjuvant chemotherapy: a pathological stage-matched comparison. BJU Int. 2025 Jan; 135(1):59-62.. View in PubMed
• FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb; 87(2):110-122.. View in PubMed
• Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma. J Endourol. 2024 11; 38(11):1156-1163.. View in PubMed
• Technical Considerations to Minimize False-Positive Findings in Blue Light Cystoscopy for Nonmuscle-Invasive Bladder Cancer. J Urol. 2025 Jan; 213(1):5-7.. View in PubMed
• Eleven-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors. J Urol. 2025 01; 213(1):60-70.. View in PubMed
• Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer? Curr Opin Urol. 2024 11 01; 34(6):489-494. Xia L, Daneshmand S . View in PubMed
• Perioperative and extended outcomes of patients undergoing parastomal hernia repair following cystectomy and ileal conduit. World J Urol. 2024 Aug 12; 42(1):482.. View in PubMed
• Opioid prescription following radical orchiectomy associated with new persistent opioid use. Urol Oncol. 2024 11; 42(11):375.e15-375.e21.. View in PubMed
• Moving the Needle in Early-Stage Testicular Germ Cell Tumor Management: The MAGESTIC Trial. J Urol. 2024 Dec; 212(6):907-909.. View in PubMed
• Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.. View in PubMed
• Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024 Dec; 7(6):1267-1279.. View in PubMed
• Reply by Authors. J Urol. 2024 07; 212(1):50-51.. View in PubMed
• A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial. J Urol. 2024 07; 212(1):41-51.. View in PubMed
• Pathologic and survival outcomes following radical cystectomy for “progressive” and “de novo” muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status. Urol Oncol. 2024 10; 42(10):333.e1-333.e13.. View in PubMed
• Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis. BJU Int. 2024 10; 134(4):526-533.. View in PubMed
• Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial. J Urol. 2024 06; 211(6):743-753.. View in PubMed
• Reply by Authors. J Urol. 2024 Jun; 211(6):751.. View in PubMed
• Update on the Management of Low-stage Seminoma. Urol Clin North Am. 2024 Aug; 51(3):377-385.. View in PubMed
• Reply by Authors. J Urol. 2024 Jun; 211(6):752-753.. View in PubMed
• Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial. Eur Urol. 2025 Feb; 87(2):271-274.. View in PubMed
• Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2024 Apr; 30(4):1211.. View in PubMed
• Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry. Cancers (Basel). 2024 Mar 24; 16(7).. View in PubMed
• The effect of enhanced recovery after surgery on oncologic outcome following radical cystectomy for urothelial bladder carcinoma. Surg Oncol. 2024 Jun; 54:102061.. View in PubMed
• Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma. J Natl Cancer Inst. 2024 03 07; 116(3):468-475.. View in PubMed
• Blood-based liquid biopsy: A promising noninvasive test in diagnosis, surveillance, and prognosis of patients with upper tract urothelial carcinoma. Urol Oncol. 2024 04; 42(4):118.e9-118.e17.. View in PubMed
• Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.. View in PubMed
• Commentary on Novitas LCD. Bladder Cancer. 2023; 9(4):305-312.. View in PubMed
• Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.. View in PubMed
• Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now? Ann Oncol. 2023 12; 34(12):1077-1079.. View in PubMed
• Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023 11; 29(11):2825-2834.. View in PubMed
• The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy. Can Urol Assoc J. 2023 Oct; 17(10):301-309.. View in PubMed
• Feminizing Adrenocortical Tumor with Multiple Recurrences: A Case Report. Case Rep Oncol. 2023 Jan-Dec; 16(1):1033-1040.. View in PubMed
• The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Bladder Cancer. 2023; 9(3):227-236.. View in PubMed
• Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023. J Urol. 2024 01; 211(1):20-25.. View in PubMed
• Reply to A. Rumyantsev et al. J Clin Oncol. 2023 11 20; 41(33):5203-5204.. View in PubMed
• Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 12 01; 41(34):5296-5305.. View in PubMed
• Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol. 2024 02; 85(2):114-122.. View in PubMed
• Metastatic Testicular Cancer Patterns and Predictors: A Contemporary Population-based SEER Analysis. Urology. 2023 Oct; 180:182-189.. View in PubMed
• Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Renal Function. Eur Urol Focus. 2024 01; 10(1):169-181.. View in PubMed
• Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus. 2023 07; 9(4):561-563.. View in PubMed
• Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.. View in PubMed
• Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023 06; 24(6):669-681.. View in PubMed
• Perioperative mortality for radical cystectomy in the modern Era: experience from a tertiary referral center. Int Braz J Urol. 2023 May-Jun; 49(3):351-358.. View in PubMed
• Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023 10; 6(5):516-524.. View in PubMed
• Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer. Eur Urol Open Sci. 2023 May; 51:39-46.. View in PubMed
• Association between early postradical cystectomy kidney injury and perioperative outcome in enhanced recovery era. Urol Oncol. 2023 09; 41(9):389.e15-389.e20.. View in PubMed
• Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018.. View in PubMed
• Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis. Cancers (Basel). 2023 Feb 23; 15(5).. View in PubMed
• Reply by Authors. J Urol. 2023 05; 209(5):862.. View in PubMed
• A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study. J Urol. 2023 05; 209(5):854-862.. View in PubMed
• Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.. View in PubMed
• Plasma Micro-RNA 371 Expression in Early-Stage Germ Cell Tumors: Are We Ready to Move Toward Biology-Based Decision Making? J Clin Oncol. 2023 05 10; 41(14):2478-2482. Alsyouf M, Nappi L, Nichols C, D . View in PubMed
• Retroperitoneal Lymph Node Dissection Should Be a Standard-of-Care Treatment Option For Stage II Seminoma. Eur Urol Open Sci. 2023 Mar; 49:67-68.. View in PubMed
• Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review. Eur Urol Focus. 2023 07; 9(4):631-636.. View in PubMed
• Primary Retroperitoneal Lymph Node Dissection in Stage I and Low-volume Metastatic Germ Cell Tumors. Eur Urol Focus. 2023 03; 9(2):248-250.. View in PubMed
• Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154.. View in PubMed
• Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. J Urol. 2023 04; 209(4):762-772.. View in PubMed

• Djaladat, Hooman
• Gill, Inderbir
• Desai, Mihir
• Cacciamani, Giovanni
• Schuckman, Anne
• Aron, Monish